Clinical trials: Diabetes Mellitus Type 2 (T2DM)
Type 2 Diabetes (T2DM)
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
- Trial name
- NCT07064486
- Testing
- BGM0504, Semaglutide
- Where
- 4 sites in Indonesia
- Volunteers
- 152 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Inflammatory Arthritis, Diabetes (DM)
Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine
The purpose of this study is to examine whether the blood test Hemoglobin A1c (HbA1c) gives an accurate picture of blood glucose levels in patients with inflammatory arthritis who are treated with sulfasalazine.
- Conditions
- Inflammatory Arthritis, Diabetes (DM), Rheumatoid Arthritis (RA), Type 1 Diabetes Mellitus
- Trial name
- DIA2SULFA (NCT07416656)
- Where
- Denmark
- Volunteers
- 75 people
- Sponsor
- Klavs Würgler Hansen
Diabetes, Obstructive Sleep Apnea
Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea
The purpose of the trial is to investigate the effects of three months' treatment with a CPAP-device versus control group on change in arterial stiffness in type 2 diabetes (T2D) patients with newly detected Obstructive Sleep…
- Trial name
- NCT02482584
- Testing
- CPAP, Control
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Nordsjaellands Hospital
Type II Diabetes Mellitus
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.
- Trial name
- NCT00995787
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA).
- Trial name
- CRISTALSEA (NCT07532863)
- Testing
- No treatment given
- Where
- 6 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM), Insulin Resistance
Therapeutic Strategies for Type 2 Diabetes Based on Lifestyle Changes: Plant-based Diet and Physical Exercise
The study evaluates the impact of a strict vegetarian diet combined with regular physical exercise and the use of probiotics on metabolic, inflammatory, and epigenetic parameters in patients with type 2 diabetes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Insulin Resistance, Inflamation, Gut Microbiomes
- Trial name
- NCT06959043
- Testing
- Probiotic Supplementation
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Maria Elizabeth Rossi da Silva
Diabetes Mellitus, Type 2
Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
This study aims to determine if the addition of Canagliflozin (Invokana™) therapy to monotherapy of metformin is more effective at achieving the double composite endpoint of a reduction in HbA1c (≥ 0.3%) and weight loss (≥1kg)…
- Trial name
- Can Do (NCT02694263)
- Testing
- Canagliflozin, Repaglinide, Pioglitazone
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Leicester
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus
Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water. This study will assess whether or not GW677954 causes the body to retain fluid.
- Trial name
- NCT00437164
- Testing
- Insulin, Oral GW677954 Capsules (15 mg)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus (T2DM), Pregnancy
Association Between CGM Metrics in Type 2 Diabetes Pregnancy and Perinatal Morbidity
The purpose of this observational study is to measure the association between continuous glucose monitoring (CGM) parameters and perinatal morbidity in offspring of women with type 2 diabetes.
- Trial name
- PREG CGM (NCT06892314)
- Testing
- Exposure to hyperglycemia (type 2 diabetes)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Sud Francilien
Diabetes Mellitus, Type 2
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
To demonstrate the efficacy and safety of acarbose and metformin loose-dose combination as compared to metformin monotherapy in the treatment of subjects with T2DM that is inadequately controlled by metformin alone
- Trial name
- NCT03349684
- Testing
- Acarbose, Metformin
- Where
- 29 sites in China
- Volunteers
- 287 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT04501406
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- University of Florida
Type 2 Diabetes Mellitus (T2DM)
Endoscopic Band Ligation for Type 2 Diabetes Mellitus (ENDOBAND-DM)
This is a pilot clinical study evaluating the safety and feasibility of Endoscopic Band Ligation (ENDOBAND-DM) applied to the second through fourth parts of the duodenum - from just distal to the ampulla of Vater to the ligament…
- Trial name
- ENDOBAND-DM (NCT07117721)
- Testing
- Endoscopic Band Ligation (ENDOBAND-DM)
- Volunteers
- 10 people
- Sponsor
- El Katib Hospital
Diabetes Mellitus Type 2
Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM
Primary Objective: To demonstrate the ease of use of the U300 pen injector in pen-naïve and insulin-naïve type 2 diabetes mellitus (T2DM) patients in a 4-week once-daily dosing regimen with HOE901-U300.
- Trial name
- NCT02227212
- Testing
- Insulin glargine U300 (new formulation of insulin glargine) HOE901
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes
This study is a multicenter, randomized controlled trial to test whether an SGLT2 inhibitor (dapagliflozin), a type of diabetes medication, can slow down or even reverse the progression of coronary atherosclerosis (plaque buildup…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease, Atherosclerosis
- Trial name
- SCOPE (NCT07614230)
- Testing
- Dapagliflozin (DAPA), Standard Care (Treatment as Usual)
- Where
- 2 sites in China
- Volunteers
- 144 people
- Sponsor
- Junjie Yang
T2DM (Type 2 Diabetes Mellitus)
Group Emotion-Focused Behavioral Intervention for Diabetes Distress/A1c in T2D.
T2D is a major public health problem and is currently the 7th leading cause of death in the US. Despite a range of efficacious treatments, less than 50% of patients achieve a glycemic target of A1c < 7.0%, suggesting that this is…
- Trial name
- NCT06912737
- Testing
- Group Emotion Focused Behavioral Intervention (G-EFBI), Group - With Every Heartbeat is Life (G-WEHL)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Ohio State University
Type 2 Diabetes (T2DM)
Implementing WHO HEARTS-D Guidelines in Bangladesh for Diabetes Control and Prevention
Type-2 diabetes (T2D) is rising at an alarming rate in the low- and middle-income countries (LMIC). This rapid increase in the T2D burden has a particular impact on cities, where more than half the LMIC populations currently live…
- Trial name
- T2D IR (NCT07155902)
- Testing
- The community-to-facility integrated strategy
- Volunteers
- 5,000 people
- Sponsor
- Florida International University
Myocardial Infarction, Diabetes Mellitus, Type 2
Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients
A prospective, randomized, controlled study will be conducted at Clinical Cardioglogy department, Ain Shams University Hospitals, assessing the efficacy and tolerability of SGLT2 inhibitors (dapagliflozin) addition on the…
- Conditions
- Myocardial Infarction, Diabetes Mellitus, Type 2, Myocardial Remodeling, Ventricular
- Trial name
- NCT05335629
- Testing
- Dapagliflozin 10Mg Tab
- Where
- Egypt
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Diabetes Mellitus, Type 2
Self Titration With Apidra to Reach Target Study (START)
Primary Objective: The primary objective of this study is to demonstrate non-inferiority of a patient-managed titration algorithm (including blood glucose monitoring) for the addition of a single dose of insulin glulisine at…
- Trial name
- NCT01013571
- Testing
- insulin glargine, Apidra (insulin glulisine)
- Where
- Canada
- Volunteers
- 493 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Metabolic Syndrome
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
This is a Phase 2, multi-center, double-blind, placebo-controlled study of the safety and effect of PBI-4050 at doses ranging from 400 mg to 1200 mg on relevant biomarkers in subjects with inadequately-controlled T2DMS on stable…
- Trial name
- NCT03081598
- Testing
- PBI-4050
- Where
- 11 sites in Canada
- Volunteers
- 104 people
- Sponsor
- Liminal BioSciences Ltd.
Type 2 Diabetes Mellitus
Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)
GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo…
- Trial name
- NCT00387972
- Testing
- denagliptin (GW823093)
- Where
- 57 sites in United States
- Sponsor
- GlaxoSmithKline